Announcements Trials

Browse Landscape

Phase

Phase 1/2 3 Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Differentiated Thyroid Cancer 1

Interventions

Cisplatin 62 Carboplatin 52 Paclitaxel 48 Radiotherapy 47 Docetaxel 41 Gemcitabine 38 Cyclophosphamide 36 Rituximab 33 Capecitabine 28 Fluorouracil 27 Dexamethasone 27 Doxorubicin 26 Prednisone 21 Bevacizumab 20 Pemetrexed 19 Oxaliplatin 18 Leucovorin 18 pembrolizumab 17 Vincristine 17 Etoposide 17 Cytarabine 15 Drug Therapy 14 Irinotecan 13 Imatinib Mesylate 13 Filgrastim 13 Zoledronic Acid 12 Radiosurgery 12 Erlotinib Hydrochloride 12 Trastuzumab 11 Goserelin 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × donafenib × Clear all

NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡